The Label That Outlived the Evidence: IgA Deficiency and Transfusion

Somewhere in this patient's chart, someone typed "IgA deficient." That's it. No level, no antibody status, no history of a reaction. Just the label. And because the label exists, an order goes in for washed red cells and IgA-deficient plasma, every time, for the rest of this person's transfusion history, because that's what you do when someone is IgA deficient.

Except I'm not sure any of us fully know what we're protecting against.

What actually counts as IgA deficient, for us

Immunology's threshold for selective IgA deficiency is a serum IgA under 7 mg/dL with normal IgG and IgM. That's common. Estimates range from roughly 1 in 300 to 1 in 1,000 people in Western populations, depending on the study and the assay [1][2]. This is not a zebra. Most of these people are asymptomatic and will never know they have it.

Transfusion medicine uses a stricter cutoff: less than 0.05 mg/dL, confirmed by a specialized assay currently available only as a send-out through the American Red Cross. A result below that threshold reflexes automatically to anti-IgA antibody testing. So the actual transfusion-relevant workup is a two-step process, hard to access, testing for a rarer and more severe deficiency than the general immunology definition implies.

And then, once you have both pieces, severe deficiency confirmed and anti-IgA detected, you still don't have an answer to the question that actually matters: will this person react.

Anti-IgA is common, and its presence doesn't tell you much

Roughly 20 to 40% of IgA-deficient patients develop anti-IgA antibodies [2][3]. If presence of the antibody reliably predicted anaphylaxis, that would be a lot of predictable anaphylaxis. It isn't, and it doesn't.

The most direct evidence against pathogenicity comes from Robitaille et al., who compared transfusion outcomes from IgA-deficient donors with and without anti-IgA and found no increased rate of allergic reactions in recipients of anti-IgA-containing components [4]. A separate study of apheresis platelets from anti-IgA-positive, IgA-deficient donors found the same thing: no meaningful increase in reactions compared to standard donors [5]. People are, apparently, routinely receiving anti-IgA passively and tolerating it without incident.

The literature on the other side isn't clean either. Case series and reviews describe patients with anti-IgA and no reactions, and patients with reactions and no detectable anti-IgA, with no consistent relationship between antibody titer and reaction severity [6][7]. Some patients who reacted once to one product subsequently tolerated other IgA-containing products without issue. If anti-IgA were the mechanism, that inconsistency shouldn't exist.

The numbers, put together

Transfusion-related anaphylaxis overall happens in roughly 1 in 20,000 to 1 in 47,000 transfusions [2][8]. Of anaphylactic transfusion reactions specifically, anti-IgA is estimated to account for somewhere around 1 to 5% in Caucasian populations [8], and at least one estimate puts anti-IgA-attributable anaphylaxis at under 1 in 500,000 components transfused [8].

So: a rare event overall, a small fraction of that rare event plausibly attributable to anti-IgA, and even within that fraction, an antibody whose presence doesn't reliably distinguish who reacts from who doesn't.

What guidelines actually say, versus what charts actually say

This is where it gets interesting, because the professional guidance is more conservative than routine practice. Canadian Blood Services recommends anti-IgA testing only after a documented anaphylactic reaction or two severe allergic reactions, not as a prophylactic screen [8]. Pathology references summarizing current practice are blunter still: IgA-deficient patients should be worked up appropriately and do not require washed products unless a documented severe reaction has already occurred [9].

That is not what "IgA deficient" typically triggers in practice. In practice, the label alone, often without a confirmed level, without antibody testing, and without any reaction history, is enough to generate a standing order for washed cellular products and IgA-deficient plasma indefinitely.

Where I land

I think we overtreat this. Not recklessly, and not without a defensible history behind why the practice exists. But the evidence base for "anti-IgA in the absence of a prior reaction requires special products" is thinner than the reflexiveness of the ordering pattern suggests. The one group where the caution is clearly earned is the subset with severe deficiency by the strict cutoff, confirmed anti-IgA, and a documented prior reaction. Everyone else on this spectrum, and it's a wide spectrum given how common IgA deficiency actually is, may be getting a more restrictive product than the data justify.

I don't think this is a case of the evidence being ignored so much as the evidence never quite catching up to the caution that got built into practice decades ago, and nobody circling back to ask whether the caution still fits what we now know. Washing red cells and sourcing IgA-deficient plasma isn't free. It costs time, it costs product availability, and for a rare-antigen patient already competing for limited units, it can mean the difference between finding compatible blood in an hour versus a day.

So the next time "IgA deficient" shows up in a chart with no further detail, I think the right question isn't "did we wash the cells." It's "do we actually know this patient needs that."

References

1. Fernandez J, Mandell BF. Selective IgA Deficiency. MSD Manual Professional Edition. Reviewed/Revised October 2024.

2. Selective IgA Deficiency. StatPearls [Internet]. NCBI Bookshelf. NBK538205. Updated June 26, 2023.

3. Transfusion Selective IgA Deficiency. StatPearls [Internet]. NCBI Bookshelf. NBK564340. Updated February 24, 2025.

4. Robitaille N, Delage G, Long A, Thibault L, Robillard P. Allergic transfusion reactions from blood components donated by IgA-deficient donors with and without anti-IgA: a comparative retrospective study. Vox Sang. 2010;99(2):136-141.

5. Winters JL, et al. Transfusion of apheresis PLTs from IgA-deficient donors with anti-IgA is not associated with an increase in transfusion reactions. Transfusion. 2004;44(3):382-389.

6. Collet A, de Chambure DP, Moitrot E, et al. Non-allergic Hypersensitivity Reactions to Immunoglobulin Preparations in Antibody Deficiencies: What Role for Anti-IgA IgG and Complement Activation? Clin Rev Allergy Immunol. 2024.

7. Odineal DD, Gershwin ME. The Epidemiology and Clinical Manifestations of Autoimmunity in Selective IgA Deficiency. Clin Rev Allergy Immunol. 2020.

8. Anaphylactic transfusion reactions and IgA deficiency. Canadian Blood Services Professional Education. Accessed 2026.

9. Allergic / anaphylactic. Transfusion medicine. PathologyOutlines.com. Accessed September 2026.